In conclusion, TRC120038, a dual AT1/ETA receptor blocker, has clearly shown its multifaceted potential in controlling hypertension and attenuating diabetic end organ damage in a way similar, or even better (in several aspects) than candesartan. This evidence concerns the gene AGTR1 and hypertensive disorder.